ESMO 2022:Sacituzumab Govitecan-hziy在HER2-低表达/HER2-0转移性乳腺癌中显示出有前景的疗效(TROPiCS-02研究)

2022-09-12 MedSci原创 MedSci原创

乳腺癌是女性癌症死亡的第二大原因,HR+/HER2-是最常见的分型,约占所有乳腺癌的70%。序贯内分泌治疗(ET)联合靶向药物是转移性HR+/HER2-乳腺癌的标准治疗,国际指南推荐HR+/HER2-

乳腺癌是女性癌症死亡的第二大原因,HR+/HER2-是最常见的分型,约占所有乳腺癌的70%。序贯内分泌治疗(ET)联合靶向药物是转移性HR+/HER2-乳腺癌的标准治疗,国际指南推荐HR+/HER2-乳腺癌一线使用ET联合CDK4/6抑制剂(CDK4/6i),但对于ET + CDK4/6i治疗进展后的最佳方案尚未明确。对于ET耐药患者来说,序贯单药化疗是标准治疗,但疗效有限且毒性反应大。而在后线治疗中很少有化疗选择可用,仍存在高度未满足的临床需求。

Sacituzumab Govitecan-hziy(戈沙妥珠单抗)是一种首创靶向Trop-2的ADC药物。Trop-2是一种跨膜钙信号转导因子,与肿瘤进展和不良预后相关,在大约80%的乳腺癌中高表达,无论何种亚型。戈沙妥珠单抗此前已获批用于治疗转移性三阴性乳腺癌(mTNBC)。在HR+/HER2-转移性乳腺癌患者的I/II期临床试验IMMU-132-01研究中,戈沙妥珠单抗显示出理想的临床结果且安全性可控,研究者评估的ORR为31.5%,中位PFS为5.5个月,中位OS为12个月。

TROPiCS-02研究是III期临床试验,旨在评估SG治疗HR+/HER2-局部复发不可手术或转移性乳腺癌的疗效和安全性。纳入标准:转移性或局部复发性不可手术的HR+/HER2-乳腺癌,在任何情况下至少经历1线内分泌治疗、紫杉烷和CDK4/6i,转移性疾病化疗线数≥2(但≤4线),辅助或新辅助治疗一年内进展,根据RECIST 1.1评估可测量病灶。研究共入组543例患者,按1:1随机分配至SG组和医生选择治疗组(TPC)。研究的主要终点是BICR评估的PFS,次要终点包括OS、ORR和DOR等。

图片

详细见:ASCO2022 | TROPiCS-02临床重磅发布:戈沙妥珠单抗使HR+/HER2-MBC进展或死亡降低34%!

图片

这次在ESMO 2022会议上报告了亚组分析,Sacituzumab Govitecan-hziy(Trodelvy)改善了激素受体阳性转移性乳腺癌HER2低表达或HER2免疫组织化学检测结果为零(IHC0)的HER2低表达患者的无进展生存期(PFS)和总缓解率(ORR)。

德国曼海姆大学的Frederik Marmé博士在ESMO2022大会期间介绍了研究结果时说:“HER2低表达是相对新定义的阴性患者亚组,约占HR阳性/HER2阴性乳腺癌患者的65%。

分配至sacituzumab govitecan组的HER2低表达疾病患者的中位PFS优于医生选择的治疗(6.4 vs 4.2个月;HR,0.58;95%CI,0.42-0.79;P<0.001)。在IHC0(5.0 vs 3.4个月;HR,0.72;0.51-1.00;P=0.05)和意向治疗(ITT;5.5 vs 4.0个月;HR,0.66;95%CI,0.53-0.83;P=0.0003)人群中,sacituzumab govitecan的PFS同样优于医生选择的治疗。

“本研究表明,与医生选择的治疗相比,sacituzumab govitecan可改善HER2低表达和激素受体阳性、HER2阴性转移性乳腺癌患者的疗效结局。这些结果与TROPiCS-02在ITT人群中的总体研究结果一致,”Marmé说,“无论 HER2 IHC 状态如何,Sacituzumab govitecan应被视为HR阳性、HER2阴性转移性乳腺癌患者的有效治疗选择。”

TROPiCS-02试验的研究者入组了543例既往接受过紫杉烷、内分泌治疗、CDK4/6抑制剂和2-4线既往化疗的患者。患者在21天周期的第1天和第8天随机接受10mg/kg sacituzumab govitecan或医生选择的治疗,直至疾病进展或出现不可接受的毒性。

对于该回顾性亚组分析,研究者评价了当地IHC和原位杂交,以通过HER IHC状态确定疗效。

52%的患者为HER2低表达,其中149例分配至sacituzumab govitecan组,134例分配至医生选择治疗组。40%的患者为IHC0,其中,101例被分配至sacituzumab govitecan组,116例被分配至医生选择的治疗组。43例患者因IHC状态缺失而从分析中排除。

在HER2低表达人群(26% vs 12%;比值比[OR],2.52;95%CI,1.33-4.78)和ITT人群(21% vs 14%;OR,1.63;95%CI,1.04-2.55)中,ORR有利于sacituzumab govitecan。然而,抗体偶联药物(ADC)未改善IHC0队列的ORR(16% vs 15%;OR,1.10;95%CI,0.52-2.30)。

HER2低表达组的中位缓解持续时间(DOR)为7.4个月(95%CI,5.8-8.9),而sacituzumab govitecan组为4.1个月(95%CI,2.8-6.1)。同样,在IHC0(8.1 vs 6.1个月)和ITT(7.4 vs 5.6个月)亚组中,sacituzumab govitecan组的DOR更优。

Marmé说:“sacituzumab govitecan在HER2低表达和HER2零表达亚组中的安全性特征与总体TROPiCS-02安全性人群基本一致。”

Peter MacCallum癌症中心Shom Goel教授提供了对研究结果的观点。他指出,HER2低表达和IHC0之间的差异“非常模糊”,将IHC0与IHC1分开的病理检查之间的一致性“实际上相当差”。随着越来越多的ADC进入市场,靶向各种不同的靶点,我们必须非常小心,试图使用非常不完善的工具对乳腺癌进行分类和重新分类是缺乏生物学基础的。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (11)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1738616, encodeId=5d451e3861672, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4763, encryptionId=a9dd4e63c4, topicName=CIT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eabf34462441, createdName=12498877m109暂无昵称, createdTime=Sat Oct 01 07:29:52 CST 2022, time=2022-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912898, encodeId=9d53191289848, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Tue Feb 07 05:29:52 CST 2023, time=2023-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024947, encodeId=e88e202494eb3, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16459, encryptionId=c27516459de, topicName=SMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Fri Nov 25 16:29:52 CST 2022, time=2022-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2080921, encodeId=ce942080921ad, content=<a href='/topic/show?id=6d0260588eb' target=_blank style='color:#2F92EE;'>#有前景#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60588, encryptionId=6d0260588eb, topicName=有前景)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5319428, createdName=jjjiang0199, createdTime=Tue May 23 16:29:52 CST 2023, time=2023-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050306, encodeId=9efb2050306c1, content=<a href='/topic/show?id=a907818429' target=_blank style='color:#2F92EE;'>#Govitecan#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8184, encryptionId=a907818429, topicName=Govitecan)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Tue Jan 03 05:29:52 CST 2023, time=2023-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652542, encodeId=3c3f1652542ff, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Sat Nov 05 13:29:52 CST 2022, time=2022-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982563, encodeId=d7fc1982563c1, content=<a href='/topic/show?id=da628e19d5' target=_blank style='color:#2F92EE;'>#HER2-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8719, encryptionId=da628e19d5, topicName=HER2-)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e093393, createdName=luwei00, createdTime=Thu May 18 05:29:52 CST 2023, time=2023-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281084, encodeId=7e17128108456, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7021, encryptionId=50d6e0215a, topicName=ESMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7460166, createdName=zhang92560, createdTime=Tue Sep 13 19:29:52 CST 2022, time=2022-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341503, encodeId=9c3d134150331, content=<a href='/topic/show?id=f4e515829b7' target=_blank style='color:#2F92EE;'>#Sacituzumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15829, encryptionId=f4e515829b7, topicName=Sacituzumab)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/C4Qhy5XHSe503Qbjzc1UtDR83BCv66o6P2XRedX9ohsNGa3uEVicFFk2qkuX5zBSmpicepFySBrwoYknhqMdKmtw/132, createdBy=1aca2500179, createdName=12498d2fm51(暂无昵称), createdTime=Tue Sep 13 19:29:52 CST 2022, time=2022-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387034, encodeId=b142138e0348f, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Sep 13 19:29:52 CST 2022, time=2022-09-13, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1738616, encodeId=5d451e3861672, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4763, encryptionId=a9dd4e63c4, topicName=CIT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eabf34462441, createdName=12498877m109暂无昵称, createdTime=Sat Oct 01 07:29:52 CST 2022, time=2022-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912898, encodeId=9d53191289848, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Tue Feb 07 05:29:52 CST 2023, time=2023-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024947, encodeId=e88e202494eb3, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16459, encryptionId=c27516459de, topicName=SMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Fri Nov 25 16:29:52 CST 2022, time=2022-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2080921, encodeId=ce942080921ad, content=<a href='/topic/show?id=6d0260588eb' target=_blank style='color:#2F92EE;'>#有前景#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60588, encryptionId=6d0260588eb, topicName=有前景)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5319428, createdName=jjjiang0199, createdTime=Tue May 23 16:29:52 CST 2023, time=2023-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050306, encodeId=9efb2050306c1, content=<a href='/topic/show?id=a907818429' target=_blank style='color:#2F92EE;'>#Govitecan#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8184, encryptionId=a907818429, topicName=Govitecan)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Tue Jan 03 05:29:52 CST 2023, time=2023-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652542, encodeId=3c3f1652542ff, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Sat Nov 05 13:29:52 CST 2022, time=2022-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982563, encodeId=d7fc1982563c1, content=<a href='/topic/show?id=da628e19d5' target=_blank style='color:#2F92EE;'>#HER2-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8719, encryptionId=da628e19d5, topicName=HER2-)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e093393, createdName=luwei00, createdTime=Thu May 18 05:29:52 CST 2023, time=2023-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281084, encodeId=7e17128108456, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7021, encryptionId=50d6e0215a, topicName=ESMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7460166, createdName=zhang92560, createdTime=Tue Sep 13 19:29:52 CST 2022, time=2022-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341503, encodeId=9c3d134150331, content=<a href='/topic/show?id=f4e515829b7' target=_blank style='color:#2F92EE;'>#Sacituzumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15829, encryptionId=f4e515829b7, topicName=Sacituzumab)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/C4Qhy5XHSe503Qbjzc1UtDR83BCv66o6P2XRedX9ohsNGa3uEVicFFk2qkuX5zBSmpicepFySBrwoYknhqMdKmtw/132, createdBy=1aca2500179, createdName=12498d2fm51(暂无昵称), createdTime=Tue Sep 13 19:29:52 CST 2022, time=2022-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387034, encodeId=b142138e0348f, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Sep 13 19:29:52 CST 2022, time=2022-09-13, status=1, ipAttribution=)]
    2023-02-07 snf701207
  3. [GetPortalCommentsPageByObjectIdResponse(id=1738616, encodeId=5d451e3861672, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4763, encryptionId=a9dd4e63c4, topicName=CIT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eabf34462441, createdName=12498877m109暂无昵称, createdTime=Sat Oct 01 07:29:52 CST 2022, time=2022-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912898, encodeId=9d53191289848, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Tue Feb 07 05:29:52 CST 2023, time=2023-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024947, encodeId=e88e202494eb3, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16459, encryptionId=c27516459de, topicName=SMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Fri Nov 25 16:29:52 CST 2022, time=2022-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2080921, encodeId=ce942080921ad, content=<a href='/topic/show?id=6d0260588eb' target=_blank style='color:#2F92EE;'>#有前景#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60588, encryptionId=6d0260588eb, topicName=有前景)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5319428, createdName=jjjiang0199, createdTime=Tue May 23 16:29:52 CST 2023, time=2023-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050306, encodeId=9efb2050306c1, content=<a href='/topic/show?id=a907818429' target=_blank style='color:#2F92EE;'>#Govitecan#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8184, encryptionId=a907818429, topicName=Govitecan)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Tue Jan 03 05:29:52 CST 2023, time=2023-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652542, encodeId=3c3f1652542ff, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Sat Nov 05 13:29:52 CST 2022, time=2022-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982563, encodeId=d7fc1982563c1, content=<a href='/topic/show?id=da628e19d5' target=_blank style='color:#2F92EE;'>#HER2-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8719, encryptionId=da628e19d5, topicName=HER2-)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e093393, createdName=luwei00, createdTime=Thu May 18 05:29:52 CST 2023, time=2023-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281084, encodeId=7e17128108456, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7021, encryptionId=50d6e0215a, topicName=ESMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7460166, createdName=zhang92560, createdTime=Tue Sep 13 19:29:52 CST 2022, time=2022-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341503, encodeId=9c3d134150331, content=<a href='/topic/show?id=f4e515829b7' target=_blank style='color:#2F92EE;'>#Sacituzumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15829, encryptionId=f4e515829b7, topicName=Sacituzumab)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/C4Qhy5XHSe503Qbjzc1UtDR83BCv66o6P2XRedX9ohsNGa3uEVicFFk2qkuX5zBSmpicepFySBrwoYknhqMdKmtw/132, createdBy=1aca2500179, createdName=12498d2fm51(暂无昵称), createdTime=Tue Sep 13 19:29:52 CST 2022, time=2022-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387034, encodeId=b142138e0348f, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Sep 13 19:29:52 CST 2022, time=2022-09-13, status=1, ipAttribution=)]
    2022-11-25 liuhuangbo
  4. [GetPortalCommentsPageByObjectIdResponse(id=1738616, encodeId=5d451e3861672, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4763, encryptionId=a9dd4e63c4, topicName=CIT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eabf34462441, createdName=12498877m109暂无昵称, createdTime=Sat Oct 01 07:29:52 CST 2022, time=2022-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912898, encodeId=9d53191289848, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Tue Feb 07 05:29:52 CST 2023, time=2023-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024947, encodeId=e88e202494eb3, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16459, encryptionId=c27516459de, topicName=SMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Fri Nov 25 16:29:52 CST 2022, time=2022-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2080921, encodeId=ce942080921ad, content=<a href='/topic/show?id=6d0260588eb' target=_blank style='color:#2F92EE;'>#有前景#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60588, encryptionId=6d0260588eb, topicName=有前景)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5319428, createdName=jjjiang0199, createdTime=Tue May 23 16:29:52 CST 2023, time=2023-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050306, encodeId=9efb2050306c1, content=<a href='/topic/show?id=a907818429' target=_blank style='color:#2F92EE;'>#Govitecan#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8184, encryptionId=a907818429, topicName=Govitecan)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Tue Jan 03 05:29:52 CST 2023, time=2023-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652542, encodeId=3c3f1652542ff, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Sat Nov 05 13:29:52 CST 2022, time=2022-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982563, encodeId=d7fc1982563c1, content=<a href='/topic/show?id=da628e19d5' target=_blank style='color:#2F92EE;'>#HER2-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8719, encryptionId=da628e19d5, topicName=HER2-)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e093393, createdName=luwei00, createdTime=Thu May 18 05:29:52 CST 2023, time=2023-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281084, encodeId=7e17128108456, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7021, encryptionId=50d6e0215a, topicName=ESMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7460166, createdName=zhang92560, createdTime=Tue Sep 13 19:29:52 CST 2022, time=2022-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341503, encodeId=9c3d134150331, content=<a href='/topic/show?id=f4e515829b7' target=_blank style='color:#2F92EE;'>#Sacituzumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15829, encryptionId=f4e515829b7, topicName=Sacituzumab)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/C4Qhy5XHSe503Qbjzc1UtDR83BCv66o6P2XRedX9ohsNGa3uEVicFFk2qkuX5zBSmpicepFySBrwoYknhqMdKmtw/132, createdBy=1aca2500179, createdName=12498d2fm51(暂无昵称), createdTime=Tue Sep 13 19:29:52 CST 2022, time=2022-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387034, encodeId=b142138e0348f, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Sep 13 19:29:52 CST 2022, time=2022-09-13, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1738616, encodeId=5d451e3861672, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4763, encryptionId=a9dd4e63c4, topicName=CIT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eabf34462441, createdName=12498877m109暂无昵称, createdTime=Sat Oct 01 07:29:52 CST 2022, time=2022-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912898, encodeId=9d53191289848, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Tue Feb 07 05:29:52 CST 2023, time=2023-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024947, encodeId=e88e202494eb3, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16459, encryptionId=c27516459de, topicName=SMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Fri Nov 25 16:29:52 CST 2022, time=2022-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2080921, encodeId=ce942080921ad, content=<a href='/topic/show?id=6d0260588eb' target=_blank style='color:#2F92EE;'>#有前景#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60588, encryptionId=6d0260588eb, topicName=有前景)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5319428, createdName=jjjiang0199, createdTime=Tue May 23 16:29:52 CST 2023, time=2023-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050306, encodeId=9efb2050306c1, content=<a href='/topic/show?id=a907818429' target=_blank style='color:#2F92EE;'>#Govitecan#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8184, encryptionId=a907818429, topicName=Govitecan)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Tue Jan 03 05:29:52 CST 2023, time=2023-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652542, encodeId=3c3f1652542ff, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Sat Nov 05 13:29:52 CST 2022, time=2022-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982563, encodeId=d7fc1982563c1, content=<a href='/topic/show?id=da628e19d5' target=_blank style='color:#2F92EE;'>#HER2-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8719, encryptionId=da628e19d5, topicName=HER2-)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e093393, createdName=luwei00, createdTime=Thu May 18 05:29:52 CST 2023, time=2023-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281084, encodeId=7e17128108456, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7021, encryptionId=50d6e0215a, topicName=ESMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7460166, createdName=zhang92560, createdTime=Tue Sep 13 19:29:52 CST 2022, time=2022-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341503, encodeId=9c3d134150331, content=<a href='/topic/show?id=f4e515829b7' target=_blank style='color:#2F92EE;'>#Sacituzumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15829, encryptionId=f4e515829b7, topicName=Sacituzumab)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/C4Qhy5XHSe503Qbjzc1UtDR83BCv66o6P2XRedX9ohsNGa3uEVicFFk2qkuX5zBSmpicepFySBrwoYknhqMdKmtw/132, createdBy=1aca2500179, createdName=12498d2fm51(暂无昵称), createdTime=Tue Sep 13 19:29:52 CST 2022, time=2022-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387034, encodeId=b142138e0348f, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Sep 13 19:29:52 CST 2022, time=2022-09-13, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1738616, encodeId=5d451e3861672, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4763, encryptionId=a9dd4e63c4, topicName=CIT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eabf34462441, createdName=12498877m109暂无昵称, createdTime=Sat Oct 01 07:29:52 CST 2022, time=2022-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912898, encodeId=9d53191289848, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Tue Feb 07 05:29:52 CST 2023, time=2023-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024947, encodeId=e88e202494eb3, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16459, encryptionId=c27516459de, topicName=SMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Fri Nov 25 16:29:52 CST 2022, time=2022-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2080921, encodeId=ce942080921ad, content=<a href='/topic/show?id=6d0260588eb' target=_blank style='color:#2F92EE;'>#有前景#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60588, encryptionId=6d0260588eb, topicName=有前景)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5319428, createdName=jjjiang0199, createdTime=Tue May 23 16:29:52 CST 2023, time=2023-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050306, encodeId=9efb2050306c1, content=<a href='/topic/show?id=a907818429' target=_blank style='color:#2F92EE;'>#Govitecan#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8184, encryptionId=a907818429, topicName=Govitecan)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Tue Jan 03 05:29:52 CST 2023, time=2023-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652542, encodeId=3c3f1652542ff, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Sat Nov 05 13:29:52 CST 2022, time=2022-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982563, encodeId=d7fc1982563c1, content=<a href='/topic/show?id=da628e19d5' target=_blank style='color:#2F92EE;'>#HER2-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8719, encryptionId=da628e19d5, topicName=HER2-)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e093393, createdName=luwei00, createdTime=Thu May 18 05:29:52 CST 2023, time=2023-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281084, encodeId=7e17128108456, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7021, encryptionId=50d6e0215a, topicName=ESMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7460166, createdName=zhang92560, createdTime=Tue Sep 13 19:29:52 CST 2022, time=2022-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341503, encodeId=9c3d134150331, content=<a href='/topic/show?id=f4e515829b7' target=_blank style='color:#2F92EE;'>#Sacituzumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15829, encryptionId=f4e515829b7, topicName=Sacituzumab)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/C4Qhy5XHSe503Qbjzc1UtDR83BCv66o6P2XRedX9ohsNGa3uEVicFFk2qkuX5zBSmpicepFySBrwoYknhqMdKmtw/132, createdBy=1aca2500179, createdName=12498d2fm51(暂无昵称), createdTime=Tue Sep 13 19:29:52 CST 2022, time=2022-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387034, encodeId=b142138e0348f, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Sep 13 19:29:52 CST 2022, time=2022-09-13, status=1, ipAttribution=)]
    2022-11-05 shock_melon
  7. [GetPortalCommentsPageByObjectIdResponse(id=1738616, encodeId=5d451e3861672, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4763, encryptionId=a9dd4e63c4, topicName=CIT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eabf34462441, createdName=12498877m109暂无昵称, createdTime=Sat Oct 01 07:29:52 CST 2022, time=2022-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912898, encodeId=9d53191289848, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Tue Feb 07 05:29:52 CST 2023, time=2023-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024947, encodeId=e88e202494eb3, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16459, encryptionId=c27516459de, topicName=SMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Fri Nov 25 16:29:52 CST 2022, time=2022-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2080921, encodeId=ce942080921ad, content=<a href='/topic/show?id=6d0260588eb' target=_blank style='color:#2F92EE;'>#有前景#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60588, encryptionId=6d0260588eb, topicName=有前景)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5319428, createdName=jjjiang0199, createdTime=Tue May 23 16:29:52 CST 2023, time=2023-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050306, encodeId=9efb2050306c1, content=<a href='/topic/show?id=a907818429' target=_blank style='color:#2F92EE;'>#Govitecan#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8184, encryptionId=a907818429, topicName=Govitecan)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Tue Jan 03 05:29:52 CST 2023, time=2023-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652542, encodeId=3c3f1652542ff, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Sat Nov 05 13:29:52 CST 2022, time=2022-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982563, encodeId=d7fc1982563c1, content=<a href='/topic/show?id=da628e19d5' target=_blank style='color:#2F92EE;'>#HER2-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8719, encryptionId=da628e19d5, topicName=HER2-)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e093393, createdName=luwei00, createdTime=Thu May 18 05:29:52 CST 2023, time=2023-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281084, encodeId=7e17128108456, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7021, encryptionId=50d6e0215a, topicName=ESMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7460166, createdName=zhang92560, createdTime=Tue Sep 13 19:29:52 CST 2022, time=2022-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341503, encodeId=9c3d134150331, content=<a href='/topic/show?id=f4e515829b7' target=_blank style='color:#2F92EE;'>#Sacituzumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15829, encryptionId=f4e515829b7, topicName=Sacituzumab)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/C4Qhy5XHSe503Qbjzc1UtDR83BCv66o6P2XRedX9ohsNGa3uEVicFFk2qkuX5zBSmpicepFySBrwoYknhqMdKmtw/132, createdBy=1aca2500179, createdName=12498d2fm51(暂无昵称), createdTime=Tue Sep 13 19:29:52 CST 2022, time=2022-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387034, encodeId=b142138e0348f, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Sep 13 19:29:52 CST 2022, time=2022-09-13, status=1, ipAttribution=)]
    2023-05-18 luwei00
  8. [GetPortalCommentsPageByObjectIdResponse(id=1738616, encodeId=5d451e3861672, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4763, encryptionId=a9dd4e63c4, topicName=CIT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eabf34462441, createdName=12498877m109暂无昵称, createdTime=Sat Oct 01 07:29:52 CST 2022, time=2022-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912898, encodeId=9d53191289848, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Tue Feb 07 05:29:52 CST 2023, time=2023-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024947, encodeId=e88e202494eb3, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16459, encryptionId=c27516459de, topicName=SMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Fri Nov 25 16:29:52 CST 2022, time=2022-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2080921, encodeId=ce942080921ad, content=<a href='/topic/show?id=6d0260588eb' target=_blank style='color:#2F92EE;'>#有前景#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60588, encryptionId=6d0260588eb, topicName=有前景)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5319428, createdName=jjjiang0199, createdTime=Tue May 23 16:29:52 CST 2023, time=2023-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050306, encodeId=9efb2050306c1, content=<a href='/topic/show?id=a907818429' target=_blank style='color:#2F92EE;'>#Govitecan#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8184, encryptionId=a907818429, topicName=Govitecan)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Tue Jan 03 05:29:52 CST 2023, time=2023-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652542, encodeId=3c3f1652542ff, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Sat Nov 05 13:29:52 CST 2022, time=2022-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982563, encodeId=d7fc1982563c1, content=<a href='/topic/show?id=da628e19d5' target=_blank style='color:#2F92EE;'>#HER2-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8719, encryptionId=da628e19d5, topicName=HER2-)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e093393, createdName=luwei00, createdTime=Thu May 18 05:29:52 CST 2023, time=2023-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281084, encodeId=7e17128108456, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7021, encryptionId=50d6e0215a, topicName=ESMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7460166, createdName=zhang92560, createdTime=Tue Sep 13 19:29:52 CST 2022, time=2022-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341503, encodeId=9c3d134150331, content=<a href='/topic/show?id=f4e515829b7' target=_blank style='color:#2F92EE;'>#Sacituzumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15829, encryptionId=f4e515829b7, topicName=Sacituzumab)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/C4Qhy5XHSe503Qbjzc1UtDR83BCv66o6P2XRedX9ohsNGa3uEVicFFk2qkuX5zBSmpicepFySBrwoYknhqMdKmtw/132, createdBy=1aca2500179, createdName=12498d2fm51(暂无昵称), createdTime=Tue Sep 13 19:29:52 CST 2022, time=2022-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387034, encodeId=b142138e0348f, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Sep 13 19:29:52 CST 2022, time=2022-09-13, status=1, ipAttribution=)]
    2022-09-13 zhang92560
  9. [GetPortalCommentsPageByObjectIdResponse(id=1738616, encodeId=5d451e3861672, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4763, encryptionId=a9dd4e63c4, topicName=CIT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eabf34462441, createdName=12498877m109暂无昵称, createdTime=Sat Oct 01 07:29:52 CST 2022, time=2022-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912898, encodeId=9d53191289848, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Tue Feb 07 05:29:52 CST 2023, time=2023-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024947, encodeId=e88e202494eb3, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16459, encryptionId=c27516459de, topicName=SMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Fri Nov 25 16:29:52 CST 2022, time=2022-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2080921, encodeId=ce942080921ad, content=<a href='/topic/show?id=6d0260588eb' target=_blank style='color:#2F92EE;'>#有前景#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60588, encryptionId=6d0260588eb, topicName=有前景)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5319428, createdName=jjjiang0199, createdTime=Tue May 23 16:29:52 CST 2023, time=2023-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050306, encodeId=9efb2050306c1, content=<a href='/topic/show?id=a907818429' target=_blank style='color:#2F92EE;'>#Govitecan#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8184, encryptionId=a907818429, topicName=Govitecan)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Tue Jan 03 05:29:52 CST 2023, time=2023-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652542, encodeId=3c3f1652542ff, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Sat Nov 05 13:29:52 CST 2022, time=2022-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982563, encodeId=d7fc1982563c1, content=<a href='/topic/show?id=da628e19d5' target=_blank style='color:#2F92EE;'>#HER2-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8719, encryptionId=da628e19d5, topicName=HER2-)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e093393, createdName=luwei00, createdTime=Thu May 18 05:29:52 CST 2023, time=2023-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281084, encodeId=7e17128108456, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7021, encryptionId=50d6e0215a, topicName=ESMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7460166, createdName=zhang92560, createdTime=Tue Sep 13 19:29:52 CST 2022, time=2022-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341503, encodeId=9c3d134150331, content=<a href='/topic/show?id=f4e515829b7' target=_blank style='color:#2F92EE;'>#Sacituzumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15829, encryptionId=f4e515829b7, topicName=Sacituzumab)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/C4Qhy5XHSe503Qbjzc1UtDR83BCv66o6P2XRedX9ohsNGa3uEVicFFk2qkuX5zBSmpicepFySBrwoYknhqMdKmtw/132, createdBy=1aca2500179, createdName=12498d2fm51(暂无昵称), createdTime=Tue Sep 13 19:29:52 CST 2022, time=2022-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387034, encodeId=b142138e0348f, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Sep 13 19:29:52 CST 2022, time=2022-09-13, status=1, ipAttribution=)]
  10. [GetPortalCommentsPageByObjectIdResponse(id=1738616, encodeId=5d451e3861672, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4763, encryptionId=a9dd4e63c4, topicName=CIT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eabf34462441, createdName=12498877m109暂无昵称, createdTime=Sat Oct 01 07:29:52 CST 2022, time=2022-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912898, encodeId=9d53191289848, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Tue Feb 07 05:29:52 CST 2023, time=2023-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024947, encodeId=e88e202494eb3, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16459, encryptionId=c27516459de, topicName=SMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Fri Nov 25 16:29:52 CST 2022, time=2022-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2080921, encodeId=ce942080921ad, content=<a href='/topic/show?id=6d0260588eb' target=_blank style='color:#2F92EE;'>#有前景#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60588, encryptionId=6d0260588eb, topicName=有前景)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5319428, createdName=jjjiang0199, createdTime=Tue May 23 16:29:52 CST 2023, time=2023-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050306, encodeId=9efb2050306c1, content=<a href='/topic/show?id=a907818429' target=_blank style='color:#2F92EE;'>#Govitecan#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8184, encryptionId=a907818429, topicName=Govitecan)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Tue Jan 03 05:29:52 CST 2023, time=2023-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652542, encodeId=3c3f1652542ff, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Sat Nov 05 13:29:52 CST 2022, time=2022-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982563, encodeId=d7fc1982563c1, content=<a href='/topic/show?id=da628e19d5' target=_blank style='color:#2F92EE;'>#HER2-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8719, encryptionId=da628e19d5, topicName=HER2-)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e093393, createdName=luwei00, createdTime=Thu May 18 05:29:52 CST 2023, time=2023-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281084, encodeId=7e17128108456, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7021, encryptionId=50d6e0215a, topicName=ESMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7460166, createdName=zhang92560, createdTime=Tue Sep 13 19:29:52 CST 2022, time=2022-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341503, encodeId=9c3d134150331, content=<a href='/topic/show?id=f4e515829b7' target=_blank style='color:#2F92EE;'>#Sacituzumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15829, encryptionId=f4e515829b7, topicName=Sacituzumab)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/C4Qhy5XHSe503Qbjzc1UtDR83BCv66o6P2XRedX9ohsNGa3uEVicFFk2qkuX5zBSmpicepFySBrwoYknhqMdKmtw/132, createdBy=1aca2500179, createdName=12498d2fm51(暂无昵称), createdTime=Tue Sep 13 19:29:52 CST 2022, time=2022-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387034, encodeId=b142138e0348f, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Sep 13 19:29:52 CST 2022, time=2022-09-13, status=1, ipAttribution=)]

相关资讯

BREAST CANCER RES TR:亚洲数据出炉!奈拉替尼对晚期乳腺癌疗效如何?

NALA试验的亚洲亚组患者分析:比较奈拉替尼+卡培他滨(N+C)与拉帕替尼+卡培他滨(L+C)在先前接受两种或以上HER2靶向治疗的HER2+转移性乳腺癌患者中的疗效

2022年ASCO指南更新!晚期HER2阳性乳腺癌治疗如何排兵布阵最好?

随着医疗技术的不断提高,HER2阳性乳腺癌的治疗方案也在逐渐增多。但是每一种治疗方案都有其适应症,需要由专业权威的医生根据患者的病情确定最佳后续治疗方案。

Oncogene:只会助眠褪黑素?它能增强奈拉替尼对乳腺癌的治疗效果!

褪黑素通过促进HER2的内吞作用和溶酶体降解,增强Neratinib在HER2+乳腺癌中的细胞毒性作用

The Oncologist:中国胃癌患者不同HER2状态的治疗模式和预后:一项非干预注册研究(EVIDENCE)

安全性上与曲妥珠单抗和化疗已知的安全性一致; 曲妥珠单抗治疗改善了患者预后。该研究提供了一线曲妥珠单抗联合化疗治疗中国HER2阳性mGC患者的真实世界数据。

Eur J Cancer:来那替尼(Neratinib)延伸辅助治疗在HER2/HR共阳性早期乳腺癌患者的疗效和安全性分析:来自德国ExteNET研究的亚组分析结果

来那替尼(neratinib)的延伸辅助治疗可以使HER2和HR共阳性的早期乳腺癌患者临床获益。

BREAST CANCER RES TR:低风险早期乳腺癌,术后能不化疗吗?

BREAST CANCER RES TR:1期pT1N0 HER2阳性乳腺癌伴或不伴化疗的曲妥珠单抗辅助治疗:一项国家癌症数据库分析。